BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

Core Insights - BridgeBio Pharma presented a post-hoc analysis of acoramidis in the Phase 3 ATTRibute-CM study, showing significant reductions in all-cause mortality and recurrent cardiovascular-related hospitalizations [1][2] - The analysis demonstrated a 42% reduction in composite ACM and recurrent CVH events at 30 months with acoramidis compared to placebo [1] - The FDA has accepted BridgeBio's marketing application for acoramidis, with a PDUFA action date set for November 29, 2024 [2] Group 1 - The post-hoc analysis indicated a 42% reduction in composite ACM and recurrent CVH events at 30 months with acoramidis treatment compared to placebo, with a p-value of 0.0005 [1] - A 30.5% hazard reduction in ACM and recurrent CVH events at 30 months was observed using the Andersen-Gill model, with a p-value of 0.0008 [1] - The results support acoramidis as a potential first-line therapy for patients with ATTR-CM, improving overall quality of life [2] Group 2 - Transthyretin amyloidosis (ATTR-CM) is caused by the liver producing faulty transthyretin proteins, leading to abnormal protein clumps in the heart [2] - BridgeBio also presented additional data from the ATTRibute-CM study at the European Society of Cardiology 2024 [3] - Following the positive results, BBIO stock increased by 2.39% to $25.54 [3]